

ASX RELEASE

Voluntary extension of escrow for shares

Wellington, NZ, 15 March 2018: Volpara Health Technologies ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of breast screening using artificial intelligence (AI), advises that 51,482,213 shares held by the founders and directors due for release from ASX compulsory escrow on 27 April 2018, have been voluntarily escrowed for a further 12-month period from that date.

The escrow extension is a demonstration of the founders and directors commitment to the long-term success of Volpara and provides investors with an extended period of certainty regarding a significant portion of the Company's register.

The balance of shares subject to escrow extension are held by the following founders and directors:

- Roger Allen, AM (Chairman)
- Dr Ralph Highnam (CEO)
- Professor Sir Michael Brady (Founder and Director) and Lady Naomi Brady
- John F Diddams (Director)
- Professor Martin Yaffe (Founder)
- Professor Nico Karssemeijer (Founder)
- Avitwo Pty Ltd (Early investor)

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO Volpara Health Technologies ralph.highnam@volparasolutions.com t: +64 21 149 0541 Kyahn Williamson WE Buchan kwilliamson@buchanwe.com.au t: +61 3 9866 4722